The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | CASTLE trial: safety & early efficacy of anti-CD19 CAR-T therapy in systemic autoimmune diseases
Fabian Müller, MD, University Hospital Erlangen, Erlangen, Germany, discusses the final analysis of the CASTLE trial (NCT06347718), a Phase I/II basket trial exploring the safety and preliminary efficacy of the anti-CD19 CAR T-cell product zorpocabtagene autoleucel (zorpo-cel) in patients with severe refractory autoimmune diseases, including lupus, myositis, and systemic sclerosis. Dr Müller highlights that the data confirm earlier findings, with all patients responding and achieving treatment-free remission (TFR). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
